Portfolio

While the majority of my work is confidential and not publicly available, below is a selection of peer-reviewed publications in which I am acknowledged for providing medical writing support:

Alzheimer's Disease

+
  • Kurz C, Stöckl L, Schrurs I, Suridjan I, Gürsel SÜ, Bittner T, Jethwa A, Perneczky R. Impact of pre‑analytical sample handling factors on plasma biomarkers of Alzheimer’s disease. J Neurochem. 2023 Apr;165(1):95‑105. doi:10.1111/jnc.15757.

Diabetes

+
  • Rossing P, Benamar M, Cheng AY, Kumar B, Laugesen C, Bajaj HS. Efficacy and hypoglycaemia outcomes with once‑weekly insulin icodec versus once‑daily basal insulin in individuals with type 2 diabetes by kidney function: a post‑hoc participant‑level analysis of the ONWARDS 1–5 trials. Diabetes Obes Metab. 2024;26(3):485‑496. doi:10.1111/dom.16231.
  • Philis‑Tsimikas A, Krogsdahl JB, Fu A, Kellerer M, Salvesen‑Sykes K, Bain SC. Insights on hospitalisations from the Phase 3a ONWARDS 1–6 trials of once‑weekly insulin icodec. Diabetes Ther. 2025;16:1615‑1631. doi:10.1007/s13300‑025‑01745‑4.
  • Li Y, Kar S, Luan Z, Zhong X, Mu Y, et al. Once‑Weekly Insulin Icodec Versus Once‑Daily Insulin Degludec in Insulin‑Naive Chinese Participants With Type 2 Diabetes: A Post Hoc Analysis of ONWARDS 3. Diabetes Ther. 2025;16:685‑699. doi:10.1007/s13300‑025‑01701‑2.
  • Watada H, Ásbjörnsdóttir B, Nishida T, Nishimura R, Yamamoto Y, Yamauchi T, Kadowaki T. Efficacy and safety of once‑weekly insulin icodec versus once‑daily basal insulin in Japanese individuals with type 2 diabetes: a subgroup analysis of the ONWARDS 1, 2 and 4 trials. Diabetes Obes Metab. 2024;26(1):50‑60. doi:10.1111/dom.15960.
  • Hayashino Y, Tsuboi S, Yamamoto Y, Ishii H. Burden of Current Insulin Therapy and Expectations for Future Insulin Therapy: Results from INBEING, a Web‑Based Survey in Japan. Diabetes Ther. 2024;15:2537‑2555. doi:10.1007/s13300‑024‑01664‑w.
  • Wernersson AS, Akhtar S, Frøhling KB, Sparre T. Dosing accuracy characteristics of DuraTouch®: a reusable insulin pen injector. DTOM. 2025;1(1):448‑454. doi:10.1177/29986702251388645.

Infectious Diseases

+
  • Muench P, Jochum S, Wenderoth V, Ofenloch-Haehnle B, Hombach M, Strobl M, Sadlowski H, Sachse C, Torriani G, Eckerle I, Riedel A. Development and validation of the Elecsys Anti-SARS-CoV-2 immunoassay as a highly specific tool for determining past exposure to SARS-CoV-2. J Clin Microbiol. 2020 Sep;58(10):e01694-20. doi:10.1128/jcm.01694-20.
  • Riester E, Majchrzak M, Mühlbacher A, Tinguely C, Findeisen P, Hegel JK, Laimighofer M, Rank CM, Schönfeld K, Langen F, Laengin T, Niederhauser C. Multicentre performance evaluation of the Elecsys Anti-SARS-CoV-2 immunoassay as an aid in determining previous exposure to SARS-CoV-2. Infect Dis Ther. 2021 Dec;10(4):2381-2397. doi:10.1007/s40121-021-00504-9.
  • Zhang B, Ma Q, Zhao B, Wang L, Pu C, Han X. Performance evaluation of Elecsys HIV Duo on cobas e 801 using clinical samples in China. J Med Virol. 2020 Dec;92(12):3230-3236. doi:10.1002/jmv.25845.
  • Al-Kindi H, Al-Jardani A. HIV serology false positivity among expatriates from Africa: a screening dilemma. J Med Microbiol. 2020 Jun;69(6):812-816. doi:10.1099/jmm.0.001186.
  • Kim HS, Chen X, Xu M, Yan C, Liu Y, Deng H, Hoang BH, Thuy PTT, Wang T, Yan Y, Zeng Z, Gencay M, Westergaard G, Pabinger S, Kriegner A, Nauck M, Seffner A, Gohl P, Hübner K, Kaminski WE. Frequency of hepatitis B surface antigen variants (HBsAg) in hepatitis B virus genotype B and C infected East- and Southeast Asian patients: detection by the Elecsys® HBsAg II assay. J Clin Virol. 2018 Jun;103:48-56. doi:10.1016/j.jcv.2018.04.005.

Oncology

+
  • Chan HLY, Vogel A, Berg T, De Toni EN, Kudo M, Trojan J, Eiblmaier A, Klein H-G, Hegel JK, Sharma A, Madin K, Rolny V, Lisy M-R, Piratvisuth T. Performance evaluation of the Elecsys® PIVKA-II and Elecsys® AFP assays for hepatocellular carcinoma diagnosis. JGH Open. 2022 May;6(5):292-300. doi:10.1002/jgh3.12720.

Women's Health

+
  • Stepan H, Galindo A, Hund M, Schlembach D, Sillman J, Surbek D, Vatish M. Clinical utility of sFlt-1 and PlGF in screening, prediction, diagnosis and monitoring of pre-eclampsia and fetal growth restriction. Ultrasound Obstet Gynecol. 2023 Feb;61(2):168-180. doi:10.1002/uog.26032.
  • de Loos AD, Hund M, Buck K, Meun C, Sillman J, Laven JSE. Antimüllerian hormone to determine polycystic ovarian morphology. Fertil Steril. 2021 Oct;116(4):1149-1157. doi:10.1016/j.fertnstert.2021.05.094.
  • Anckaert E, Jank A, Petzold J, Rohsmann F, Paris R, Renggli M, Schönfeld K, Schiettecatte J, Kriner M. Extensive monitoring of the natural menstrual cycle using the serum biomarkers estradiol, luteinizing hormone and progesterone. Pract Lab Med. 2021 May;25:e00211. doi:10.1016/j.plabm.2021.e00211.
  • Bosch E, Hund M, van der Does R, Caracena L, Ahlers S, Labarta E. Early detection of pregnancy after IVF and embryo transfer with hyperglycosylated hCG versus HCG+β assay. Reprod Biomed Online. 2022 Feb;44(2):349-356. doi:10.1016/j.rbmo.2021.10.007.
  • Gao J, Hund M, et al. Short-Term Prediction of Preeclampsia in Chinese Women Using the sFlt-1/PlGF Ratio: A Sub-Analysis of the PROGNOSIS Asia Study. Front Cardiovasc Med. 2021 Aug 23;8:602560. doi:10.3389/fcvm.2021.602560.
  • Jacobs MH, Reuter LM, Baker VL, Craig LTB, Sakkas D, Surrey E, Doody KJ, Jungheim ES, Bayrak AB, Hund M, Verhagen-Kamerbeek WDJ, Pardue D, Buck K, Timm B. A multicentre evaluation of the Elecsys® anti-Müllerian hormone immunoassay for prediction of antral follicle count. Reprod Biomed Online. 2019 May;38(5):845-852. doi:10.1016/j.rbmo.2018.12.041.
  • Stepan H, Hund M, Dilba P, Sillman J, Schlembach D. Elecsys® and Kryptor immunoassays for the measurement of sFlt-1 and PlGF to aid preeclampsia diagnosis: are they comparable? Clin Chem Lab Med. 2019 Sep;57(9):1339-1348. doi:10.1515/cclm-2018-1228.
  • Piltonen TT, Allegranza D, Hund M, Buck K, Sillman J, Arffman RK. Validation of an anti-Müllerian hormone cutoff for polycystic ovarian morphology in the diagnosis of polycystic ovary syndrome in the HARMONIA study: protocol for a prospective, non-interventional study. JMIR Res Protoc. 2024 Feb 6;13:e48854. doi:10.2196/48854.
  • Ohkuchi A, Masuyama H, Yamamoto T, Kikuchi T, Taguchi N, Wolf C, Saito S. Economic evaluation of the sFlt-1/PlGF ratio for the short-term prediction of preeclampsia in a Japanese cohort of the PROGNOSIS Asia study. Hypertens Res. 2021 Jul;44(7):822-829. doi:10.1038/s41440-021-00624-2.
  • Hodel M, Blank PR, Marty P, Lapaire O. sFlt-1/PlGF Ratio as a Predictive Marker in Women with Suspected Preeclampsia: An Economic Evaluation from a Swiss Perspective. Dis Markers. 2019;2019:4096847. doi:10.1155/2019/4096847.

Other

+
  • Findeisen P, Leis M, Bendig G, Grimme J, Moser E, Vogl C, Christenson R. A multicenter performance evaluation of the new Elecsys® Vitamin D total III assay versus reference isotope dilution liquid chromatography-tandem mass spectrometry and commercially available comparators. J Clin Lab Anal. 2022 Sep;36(9):e24610. doi:10.1002/jcla.24610.
  • Kitchen S, de Maat M, Nagler M, Jones R, Lowe A, Burden J, Groneberg K, Rozsnyai G. System performance evaluation of the cobas t 711 and cobas t 511 coagulation analyzers in routine laboratory settings. Blood Coagulation & Fibrinolysis. 2020 Oct;31(7):459-468. doi:10.1097/mbc.0000000000000947.
  • Yalla N, Bobba G, Guo G, Stankiewicz A, Ostlund R. Parathyroid hormone reference ranges in healthy individuals classified by vitamin D status. J Endocrinol Invest. 2019 Nov;42(11):1353‑1360. doi:10.1007/s40618‑019‑01075‑w.

Ready to Discuss Your Project?

Contact Me Today